102460.KS
REYON Pharmaceutical Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 9,910.00
−0.40%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 143.4B | 145.9B | 148.3B | 151.1B | 154.0B |
| Cost of Revenue | 112.6B | 112.2B | 75.5B | 74.3B | 72.3B |
| Gross Profit | 30.8B | 33.8B | 72.8B | 78.9B | 81.7B |
| Operating Expenses | |||||
| R&D Expense | 4.5B | 4.1B | 3.6B | 8.4B | 6.7B |
| SG&A Expense | 37.1B | 31.2B | 32.6B | 31.5B | 36.8B |
| General & Admin Expense | 9.7B | 12.8B | 13.5B | 13.6B | 13.2B |
| Selling & Marketing Expense | 13.4B | 18.4B | 19.1B | 18.0B | 23.7B |
| Other Expenses | 23.3B | 30.1B | 36.5B | 35.0B | 28.9B |
| Total Operating Expenses | 64.2B | 65.3B | 72.7B | 74.9B | 72.4B |
| Cost and Expenses | 173.4B | 177.5B | 148.2B | 147.0B | 144.7B |
| Operating Income (EBIT) | (30.1B) | (31.6B) | 79.3M | 4.0B | 9.6B |
| Non-Operating | |||||
| Interest Income | 158.6M | 225.4M | 390.0M | 801.2M | 993.1M |
| Interest Expense | 13.8B | 13.2B | 1.3B | 193.8M | 122.2M |
| Net Interest Income | (13.6B) | (13.0B) | (862.9M) | 607.3M | 870.9M |
| Other Non-Op Income/Expense | (2.2B) | 6.9B | 5.1B | (1.7M) | (2.7B) |
| Non-Operating Income (excl Interest) | (9.5B) | — | (6.3B) | (193.9M) | 3.2B |
| EBT (Pre-Tax Income) | (32.3B) | (24.7B) | 5.2B | 4.0B | 6.9B |
| Income Tax Expense | 2.0B | 5.0B | 1.0B | 448.6M | (539.8M) |
| Bottom Line | |||||
| Net Income | (34.4B) | (29.8B) | 4.2B | 3.6B | 7.4B |
| Earnings from Cont. Ops | (34.2B) | (29.6B) | 4.2B | 3.6B | 7.4B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (34.4B) | (29.8B) | 4.2B | 3.6B | 7.4B |
| Per Share | |||||
| Basic EPS | (₩1,869) | (₩1,605) | ₩226 | ₩195 | ₩415 |
| Diluted EPS | (₩1,869) | (₩1,605) | ₩226 | ₩195 | ₩407 |
| Revenue Per Share | ₩7,817 | ₩7,851 | ₩8,086 | ₩8,237 | ₩8,677 |
| Shares | |||||
| Basic Shares Outstanding | 18.3M | 18.6M | 18.3M | 18.3M | 17.8M |
| Diluted Shares Outstanding | 18.3M | 18.6M | 18.3M | 18.3M | 17.8M |
| Profitability Metrics | |||||
| EBITDA | (15.0B) | 228.1M | 12.8B | 9.0B | 13.5B |
| D&A | 32.4B | 31.8B | 6.3B | 4.8B | 4.5B |
| EBIT | (47.4B) | (31.6B) | 6.4B | 4.2B | 9.0B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026